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Abstract
Purpose of Review This review aims to outline the utility of cardiac magnetic resonance (CMR) in patients with different types of
muscular dystrophies for the assessment of myocardial involvement, risk stratification and in guiding therapeutic decisions.
Recent Findings In patients suffering from muscular dystrophies (MD), even mild initial dysfunction may lead to severe heart
failure over a time course of years. CMR plays an increasing role in the diagnosis and clinical care of these patients, mostly due to
its unique capability to precisely characterize subclinical and progressive changes in cardiac geometry, function in order to
differentiate myocardial injury it allows the identification of inflammation, focal and diffuse fibrosis as well as fatty infiltration.
CMRmay provide additional information in addition to the physical examination, laboratory tests, ECG, and echocardiography.
Summary Further trials are needed to investigate the potential impact of CMR on the therapeutic decision-making as well as the
assessment of long-term prognosis in different forms of muscular dystrophies. In addition to the basic cardiovascular evaluation,
CMR can provide a robust, non-invasive technique for the evaluation of subclinical myocardial tissue injury like fat infiltration
and focal and diffuse fibrosis. Furthermore, CMR has a unique capability to detect the progression of myocardial tissue damage
in patients with a preserved systolic function.
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Introduction
Muscular dystrophies (MDs) are a heterogeneous group com-
prising progressive myopathic disorders. The severity, age of
onset, rate of progression, and prognosis vary greatly between
the different forms. Duchenne muscular dystrophy (DMD) is
the most common inherited muscular disorder of childhood,
while myotonic dystrophy (DM) is the most common form in
adults followed by facioscapulohumeral muscular dystrophy
(FSHD), limb girdle muscular dystrophies (LGMDs), Emery-
Dreifuss muscular dystrophy (EDMD), and other less frequent
forms [1]. Table 1 provides an overview of the pathologies
discussed in this review.
Despite the great variety, all of them have three features in
common: 1) they affect the musculoskeletal apparatus leading to
weakness and progressive disabilities; 2) they typically affect
patients at a young age from 5 to 30 years; 3) they all can present
with cardiac involvement manifested as heart failure, atrial and/
or ventricular arrhythmias, and conduction abnormalities. It is
important to verify whether the symptoms, e.g., dyspnea, fa-
tigue, chest pain, are caused by cardiac disorders. Especially,
the progressive muscle weakness and the significantly reduced
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mobility can mask cardiac involvement. Arrhythmias and con-
duction abnormalities can often be symptomless even in ad-
vanced stages of the disease. Therefore, it is important to assess
whether a subclinical cardiac involvement is present.
In someMDs, such asDMDandBMD, cardiac involvement
is well known and may occur in up to 90% of patients [2]. Due
to the very high risk of developing a dilated cardiomyopathy
(DCM), these patients should receive prophylactic heart failure
treatment even before the onset of symptoms [10]. That is the
reason why, especially in DMD and BMD patients, it is impor-
tant to identify cardiac involvement as soon as possible, in order
to initiate a possibly cardio-protective therapy and to limit the
progression of heart failure [11].
In the recent years, progress was made regarding the treat-
ment of patients with MD. Available therapies can help to
reduce symptoms. Ongoing research on new treatment strate-
gies including gene-based approaches are promising in differ-
ent types ofMD.Most of them are focusing on neuromuscular
limitations with the intention to preserve the functional capac-
ity as long as possible. Cardiovascular manifestations are
targeted as well in studies, and first results confirmed that a
proactive strategy of early cardiological diagnosis and treat-
ment is essential to maximize the duration and quality of life
of these patients [10, 12, 13]. The results of these studies are
reflected in present recommendations for diagnosis and man-
agement of DMD patients advocating a complete cardiac eval-
uation and early initiation of cardio-protective therapies [14].
Following the latest DMD recommendations, cardiovascular
magnetic resonance (CMR) should be considered for baseline
assessment in DMD patients already at the age of 10, when it
can typically be done without anesthesia [15••].
CMR is accepted as the reference method for assessing ven-
tricular and atrial volumes, systolic function, and regional wall
motion abnormalities. CMR is a non-invasive imaging tech-
nique that has the unique capability to detect and follow the
progression of myocardial tissue damage such as edema, focal
and diffuse fibrosis, and fat infiltration, even in the context of a
preserved systolic function. Because of its high spatial resolu-
tion, CMR can differentiate various scar patterns and detects
areas with diffuse fibrosis or edema, e.g., with T1- and T2-
mapping techniques. There is growing evidence underlying
the strength and additive value of CMR in identifying patients
at risk in different cardiac diseases. [16] The presence of focal
fibrosis in patients with non-ischemic cardiomyopathies strong-
ly predicts adverse cardiac outcome and is a negative predictor
of functional recovery and prognosis [17–19]. The presence of
focal fibrosis in patients with hypertrophic cardiomyopathy, a
so-called risk modifier, helps in the decision-making for bor-
derline patients regarding an implantable cardiac defibrillator
(ICD). Furthermore, diffuse myocardial fibrotic changes seem
to be independently associated with complex ventricular ar-
rhythmias [20], and an identification of myocardial edema is
associated with a long-term outcome [21]. Similarly, DMD and
BMD are often associated with myocardial fibrosis as a poten-
tial substrate for ventricular arrhythmias which can increase in
burden load concurrently with worsening of myocardial remod-
eling and function [16, 22, 23].
Nowadays, with increasing life expectancies of patients, at-
tending physicians have to take lifestyle choices, comorbidities,
and diseases of the elderly into consideration when approaching
the individual patient and therapy. Elder patients with muscular
dystrophies prove to be a challenge as they often exhibit age-
related disorders like atherosclerosis, metabolic impairments in
the form of elevated lipid levels or diabetes mellitus, wear-and-
tear diseases of the musculoskeletal system, as well as
neurocognitive disorders, which can mimic and exacerbate
symptoms of the underlying muscular conditions. That differs
depending on age and the kind of MD. Most of the patients are
young and an exclusion of non-ischemic myocardial injury is
usually the first-line approach. Since markers of cardiac injury,
like troponin or CK-MB, are very often elevated, the confirma-
tion or exclusion of active inflammation and detection of fibro-
sis applying CMR is most important and protocols fitted for the
detection of myocarditis are usually the first-choice. Of course,
in cases where patients present symptoms of CAD and co-
existing risk factors, we use CMR stress-protocols for a fast
and accurate detection of hemodynamically relevant coronary
artery stenoses.
This review will give an overview of the current recom-
mendations, new evidence, and how these patients should be
managed in a team effort of neurologists and cardiologists.
Regarding the cardiac involvement, we will focus on CMR
findings and its diagnostic role in the detection of myocardial
involvement, risk stratification, guiding therapeutic manage-
ment, and follow-up in patients suffering from MD.
Duchenne and Becker Muscular Dystrophies
DMD and BMD are classified as dystrophinopathies as both are
due to X-linked recessively inherited mutations in the gene that
encodes for the protein dystrophin. Major differences between
the pathologies are the type of mutations, onset, severity, and
progress of symptoms. The majority of DMD will develop a
cardiomyopathy by the age of 18. The available date shows a
median survival of 24 years for a cohort of patients with molec-
ularly confirmed DMD. In BMD patients, the frequency of
cardiac involvement can reach up to 60–75%. The average life
expectancy in this patient group is about 40 to 50 years and
death is most commonly due to dilated cardiomyopathy [24].
DMD, with an estimated prevalence of 1 per 3000 births,
the most common hereditary muscular dystrophy, usually
starts showing signs at an age of 3–5 years with a severe and
progressive clinical course. The proximal lower limb muscles
are affected first leading to a waddling gait, inability to jump
or run, the pathognomonic Gowers sign, and wheelchair
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dependency by the age of 12. During this non-ambulatory
phase, a progressive decline in ventilatory capacities sets in
leading finally to the need for non-invasive ventilation.
Majority of patients do not survive their third decade of life
due to respiratory or cardiac failure [2]. DCM and impaired
left ventricle systolic function are the primary causes of car-
diac death in a high proportion of patients with DMD and
BMD. The frequency of cardiac involvement can reach up
to 90% [25]. Interestingly, Winterholler et al. could identify
a connection between the increased risk for ischemic strokes
and DMD-associated cardiomyopathy without evidence of
atrial fibrillation. DCM was the only risk factor for ischemic
stroke in all patients [26].
Persistent sinus tachycardia is the most common detectable
rhythm deviation from normal sinus rhythm in DMD. In ad-
dition to the DCM, patients can present with signs and symp-
toms of ventricular and supraventricular tachycardias [27–29],
mitral and tricuspid insufficiency, left-sided heart failure, and
SCD [30]. Current expert care considerations have advised to
establish baseline evaluation by resting ECG and a non-
invasive imaging method, either transthoracic echocardiogra-
phy (TTE) or CMR with an annual follow-up [15••]. CMR is
the preferred imaging modality for baseline assessment in pa-
tients with poor acoustic window offering, in addition to other
non-invasive imaging methods, the ability to detect macro-
scopic findings like fat infiltration or focal fibrosis by late
gadolinium enhancement (LGE) [31, 32] (Fig. 1). However
especially in younger patients until the age of 6–7 years, TTE
is the preferred imaging method due to a lower compliance
[15••]. The myocardial fibrosis in DMD has a progressive
course and correlates with left ventricular (LV) dilation and
reduction in the ejection fraction (EF) [33, 34]. The pres-
ence of myocardial fibrosis detected by LGE has negative
implications on the prognosis and is associated with an
increased risk for cardiovascular adverse events [13].
Even in the absence of LGE, CMR seems to be able to
detect myocardial damage by the application of parametric
mapping techniques. These novel methods play an increas-
ing role in CMR, especially regarding the evaluation of
inflammation and diffuse, subclinical fibrotic changes.
Patients with DMD often have increased native T1 and
extracellular volume (ECV) values in myocardial regions
without LGE, and therefore mapping techniques seem to
have the unique ability to identify early cardiac changes
in DMD [35]. Interestingly, a recent study showed an in-
verse relationship between LGE-positive segments and T1
values attributing this to a fibrofatty replacement [36].
Further research is needed to verify the aspect of fat infil-
tration as a major contributor to the pathophysiology.
Furthermore, DMD patients with myocardial inflammation
in CMR show a rigorous progression to heart failure [37,
38].
As far as medical treatment goes, the focus should lie on
an early initiation of heart failure treatment if possible
when abnormalities are found during imaging even before
the onset of symptoms [15••]. Current standard of care
should follow adult heart failure guidelines by starting with
angiotensin-converting enzyme inhibitors (ACE) or
Fig. 1 LV dilatation (EDV 201 ml) and severe systolic dysfunction (LVEF
32%) in a 21-year-old patient with DMD. Cine imaging in a long-axis four-
chamber view (1a) and short axis (1b) and reduced global longitudinal strain
(− 10.6%) (3a). Late Gadolinium Enhancement showing extensive focal
non-ischemic enhancement in LV (arrows, 2a-b) corresponding with
increased extracellular volume (ECV) in short axis (arrows 3b)
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angiotensin II receptor blockers (ARB) [14, 39]. Recent
evidence suggests that the mineralocorticoid antagonists
(MRA) spironolactone and eplerenone could possibly de-
lay the decline of LV contractile function in DMD patients
[40, 41]. So far, the use of β-adrenergic blockade (beta
blockers (BB)) is recommended only in patients who pres-
ent with a reduced EF at baseline. Without other indica-
tions, e.g., arrhythmias, the prescription of BB to delay or
prevent the onset of DCM is currently not recommended.
Patients with fluid retention due to ventricular dysfunction
should be treated with diuretic agents. Currently, there is
no data to support the routine use of glucocorticoids (GCS)
in order to improve cardiac function; however, GCS might
be prescribed to slow the progression of cardiac disease in
patients with DMD [42].
Female carriers of DMD or BMD are also at risk of
developing a cardiomyopathy. In contrast to DMD males,
female carriers may not develop clinically apparent periph-
eral muscular disease but can instead present with a wide
range of cardiac disorders including heart failure and SCD
[43]. Cardiac involvement may develop in up to 50% of
cases [44].
BMD, incidence 1:18,000, on the other hand, is the
milder form of the dystrophinopathies. Onset of symptoms
starts usually between the 6th and 20th year of life and
patients keep their ability to walk until the age of 16 or
sometimes even longer. Interestingly, cardiac involvement
is often more prominent than musculoskeletal symptoms
and the major contributor to the symptomatic load [3,
45]. Approximately 70% of BMD patients develop a
DCM, mostly in the third decade of life or later. Usually,
the degree of skeletal muscle involvement does not corre-
late with the severity of the cardiomyopathy. Furthermore,
cardiac death seems to be more common in BMD than in
DMD [24]. Early echocardiographic studies in the 1990s
could already show that especially right ventricular wall
motion abnormalities are observable [24]. Twenty years
later, Yilmaz et al. used CMR in their cohort and could
not only confirm these results but on top prove that LGE
goes hand-in-hand with a reduction of LV ejection fraction
(LVEF) [23]. Typically, LGE in BMD follows a
subepicardial or midwall pattern with progression to a
transmural scar and is located in the inferolateral region
of the LV (Fig. 2). Our approach to cardiovascular care
and treatment is similar to the one outlined above for
DMD especially in the light of recent evidence that even
very young patients in their 2nd decade of life could have
already first signs of myocardial fibrosis [46]. Complete
cardiac evaluation should begin at approximately the age
of 10 or at the onset of signs and symptoms. Cardiological
evaluations should continue at least biannually [44].
Emery-Dreifuss Muscular Dystrophy
In contrast to the aforementioned muscular dystrophies,
EDMD, also called humeroperoneal muscular dystrophy,
can be inherited as an X-linked recessive, autosomal re-
cessive (AR), or autosomal dominant (AD) disease, the
latter one being the most common. The main reason for
this heterogeneity is the wide array of mutations account-
ing for the disease. So far 7 subpopulations (EDMD1-
EDMD7) have been identified with the majority having
variants in genes encoding nuclear membrane proteins,
therefore termed nuclear envelopathies. The AD and AR
forms, for example, can be linked to the LMNA gene
encoding for lamin A and C (EDMD2 and EDMD3) as
well as to the SYNE1 and SYNE2 genes encoding nespirin
1 (EDMD4) and 2 (EDMD5), respectively [47]. The X-
linked forms, EDMD1 and EDMD6, on the other hand,
are due to mutations on the EMD gene encoding for
emerin and the FHL1 gene encoding for LIM domain pro-
tein 1, respectively. As more and more genes and muta-
tions are deciphered, the link between muscular and car-
diac abnormalities becomes clearer. Recent research sug-
gests that patients with mutations in the EMD gene can
present solely as a cardiac phenotype, termed cardiac
emerinopathy, with probable association with left ventric-
ular noncompaction (LVNC) and an increased risk of
thromboembolic events [48]. The classic triad consists of
contractures, especially of the elbow, humeroperoneal
muscle weakness, and cardiac disorders. The cardiac man-
ifestations include DCM and associated symptoms, SCD,
and atrioventricular rhythm abnormalities [49, 50].
Cardiac involvement in EDMD often appears as atrial di-
latation in different stages (Fig. 3) which could explain the
common occurrence of supraventricular tachycardias, atri-
al fibrillation, and atrial flutter in very young patients [51,
52]. Rhythm disturbances can also be of bradycardic na-
ture (atrioventricular blocks, total atrial standstill) [52].
Macroscopic LGE changes are not very common; howev-
er, in some cases with SCD due to a ventricular tachycar-
dia, fibrotic remodeling with fat deposits in the area of the
conduction system was reported [53, 54]. Current guide-
lines of the European Society of Cardiology (ESC) recom-
mend implantation of a pacemaker (PM) as soon as first
bradyarrhythmias or other conduction abnormalities ap-
pear before the 30th year of life [55]. As Russo and
Nigro [56] mention in their letter to the editors, there is
evidence that ventricular events in EDMD can be
prevented by proper ICD implantation, and therefore rec-
ommend the combined implantation of PM-ICD devices in
patients with preserved LVEF. Given the frequent implan-
tation of PM-ICDs [57] and the rarity of the disorder, es-
timated at 1:100.000, CMR studies are limited to case
series [58].
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In addition to annual monitoring for arrhythmias with 24h-
ECG and evaluation of dilatation progress with TTE, we fol-
low the above-mentioned guidelines. Because SCD can be the
first presentation of cardiac involvement in this patient group,
cardiac screening of individuals with EDMD and first-degree
relatives (including female carriers of X-linked EDMD) is
recommended [59].
Limb Girdle Muscular Dystrophy
LGMDs are a very heterogeneous group of disorders divided
into an autosomal dominant form LGMD1 and an autosomal
recessive form LGMD2. Additionally, each group has several
subclassifications (e.g., LGMD1A-LGMD1H) based on the
gene and the muscular protein involved. In 2018 during the
European neuromuscular center (ENMC) international
workshop, a new classification system was proposed to better
replicate the new insights into the pathogenesis of LGMD
[60]. As a complete description would go beyond the scope
of this review, we will focus on the forms most commonly
associated with cardiac manifestations (in brackets the former
name, gene, and the corresponding protein): LGMDR4
(LGMD2E, SGCB, beta-sarcoglycan) and LGMDR9
(LGMD2I, FKRP, fukutin-related protein). Two additional
pathologies, in the old classification termed LGMD1B and
LGMD1E, have been excluded and reclassified under differ-
ent names with the first one being attributed to the EDMD
group and the latter now named myofibrillar myopathy
(MFM). Around 60% of patients with LGMDR4 have cardiac
manifestation including DCM, hypertrophic cardiomyopathy
(HCM), conduction abnormalities, and increased risk of SCD
[61]. Similar changes can be observed in LGMDR9 where the
decline in LVEF correlates with mortality [62]. The levels of
Fig. 2 LV dilatation (EDV 205 ml) and mild systolic dysfunction (LVEF
49%) in a 27-year-old patient with BMD. Cine imaging in a long-axis
three-chamber view (1a) and corresponding image in late gadolinium
enhancement with focal non-ischemic enhancement within inferolateral
wall in long (arrows, 1b) and short axes (arrows 1d). Native T1 map with
increased T1 native values corresponding to LGE in the short axis (arrows
1c). Green lines: slice location of the short axis
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creatinine kinase (CK) are usually severely elevated and are
one of the most common findings on presentation [63].
Possible findings during CMR exams include dilation of
the ventricles with diastolic dysfunction, subclinical fibro-
sis, and increased cardiac fat tissue [64, 65]. Myocardial fat
infiltration is less studied, but due to recent technical
developments, the identification of fatty changes has be-
come significantly easier (Fig. 4). Cardiac care should fol-
low similar principles as above, with annual visits to ex-
clude progress of arrhythmic episodes. Variants that are
not associated with an increased cardiac risk can be follow-
ed every 2 years.
Fig. 3 Biatrial dilatation in a 43-year-old patient with EDMD. Cine imaging in a long-axis two- (1a) and four-chamber view (2a). Right atrium 45 cm2.
Left atrium 30 cm2, 89 ml/m2
Fig. 4 A 45-year-old patient with LGMD2I and normal LV function
(LVEF 57%). SSFP cine in a two-chamber view in end-diastole (1a)
and end-systole (1b) with no wall motion abnormality, but with
detectable myocardial structure abnormality (arrows). A 2-chamber
view and a midventricular short axis. Fat/water imaging showing
extensive epicardial fat with subepicardial and intramural fatty
replacement of the myocardium (arrows 2a, b). Fibrosis imaging (LGE)
showing a bright signal—indicating a scar, but the bright signal indicates
fatty replacement as well (arrows 3a, b). Only the combination of LGE
and fat imaging allows the differentiation of the tissue character
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Myofibrillar Myopathy
Formerly classified under LGMDs, this disease now entails its
own clinical spectrum. The genetic mechanism for the disor-
der has been mapped to genes involved in desmin metabolism
leading to accumulation of faulty protein aggregates.
Especially, the mutation in the DES gene is associated with
cardiac symptoms [66]. Cardiomyopathies associated with
MFM can present very heterogeneously, ranging from dilated
to hypertrophic to restrictive, or even LVNC phenotypes [42].
Cardiac care should emphasize the detection of conduction
abnormalities [42, 67]. The decision regarding the implanta-
tion of a prophylactic ICD in this patient group should not
depend on EF alone but rather on the synopsis of all findings
and evaluations [42].
Facioscapulohumeral Muscular Dystrophy
FSHD is the third most common inherited muscular dys-
trophy, behind DMD and the myotonic dystrophies.
Inheritance pattern is mostly AD with frequent variants
due to sporadic mutations. Most cases, 95%, can be
mapped to the DUX4 gene on chromosome 4. Deletion
of repeat units on the long arm on the chromosome leads
to the subtype FSHD1. In contrast to this, FSHD2, al-
though phenotypically resembling FHD1, is due to muta-
tions of the SMCHD1 gene. As the group name indicates,
the muscle weakness is usually located in the facial, scap-
ular, humeral, and abdominal region, often with an asym-
metric involvement. Age of onset is highly variable, rang-
ing from infancy to the age of 20 [68]. In comparison to
other muscular dystrophies, cardiac involvement is less
common and presents in the majority of cases with con-
duction abnormalities, especially incomplete right bundle
branch blocks [7] and supraventricular arrhythmias [69].
Few case reports and series describe the DCMs and
SCDs in patients with FSHD but there is a lack of larger
prospective studies. In a recent CMR study, we could show
that patients with FSHD can have myocardial tissue chang-
es despite a normal systolic function. In our cohort, we
found LGE in 25% of patients, most commonly in the basal
inferolateral, inferior, and septal segments. Native T1 and
ECV values were significantly higher not only in LGE-
positive segments but also in the adjacent regions, suggest-
ing a diffuse interstitial fibrosis. Areas of fatty infiltration
were found in 13% of patients [70]. Nikhanj et al. showed
recently that there is evidence of elevated biomarkers, e.g.,
high sensitive troponin, with clinical relevance for the di-
agnosis of cardiomyopathies and prognosis of cardiac ad-
verse events in patients with MD [71]. As this new emerg-
ing evidence for cardiac disease in FSHD has not been
incorporated into guidelines yet [72], we would like to
explain our approach to these patients. Follow-ups are
done annually with TTE and 24h-ECG. If symptoms are
progressive or new arrhythmias are detected on 24h-ECG,
despite stable echocardiographic findings, we perform a
control CMR exam. Other cardiac comorbidities, like
chronic coronary syndrome, CHF, or arterial hypertension
(HTN), are treated according to guidelines [39, 73, 74].
Myotonic Syndromes
The myotonic syndromes are a group of disorders that share
the common trait of delayed muscular relaxation.
Interestingly, the two more common disorders, myotonic dys-
trophy type 1 (DM1) and myotonic dystrophy type 2 (DM2),
are rather multisystem diseases that can even present with no
muscular signs or symptoms at all. The other subgroup, also
termed non-dystrophic myotonias, is a group of very rare
channelopathies with the primary symptom being muscular
dysrelaxation. As they are rare even in the context of all these
rather uncommon disorders, we will not describe them here.
DM1, also known as Curschmann-Steinert disease, is
an autosomal-dominant disorder due to CTG-repeat-
expansions on the DMPK gene. The length of the repeats
correlates loosely with the severity of the disease, giving
rise to the following phenotypes: congenital, childhood,
classic, and mild. The underlying pathophysiology results
from the accumulation of faulty RNA that inhibits the
transcription of several other genes, a process called
RNA toxicity [75]. Examples of genes that are dysfunc-
tional due to transcription are the skeletal muscle chloride
channels, the insulin receptor, and cardiac troponin T.
This mechanism is one reason for the multiorgan involve-
ment in the DMs, the other one being the somatic mosa-
icism which results from an inherent instability of the
CTG repeats. The instability is especially pronounced in
the brain, skeletal muscle, and the heart. Signs and symp-
toms are presented in Table 2. DM1 is heavily associated
with cardiac disease burden, ranging from conduction dis-
orders and arrhythmias to ventricular and atrial structural
heart disease with signs and symptoms of overt heart fail-
ure [8]. Major abnormalities are AV-blocks, QTc and
QRS prolongations, increased ventricular extrasystoles,
atrial fibrillation and flatter, right and left bundle branch
blocks, as well as non-sustained ventricular tachycardias
[76•]. Groh et al investigated the, later so-called, Groh-
criteria (rhythm other than sinus, PR >240 ms, QRS >120
ms, or II/III-degree AV/block) in their study and found
out that they can be predictors of SCD in patients with
DM1 [77]. Very recent studies emphasize that SCD can
even be associated in more cases than previously thought,
with non-cardiac origin, underlying once more the multi-
system characteristic of DM1 [78].
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Regarding CMR, DM1 is associated with a non-ischemic
pattern of LGE enhancement and ECV even in subclinical
stages, indicating that the remodeling process is starting at
an early age [79–81]. In a cohort of 80 patients, Hermans
et al. found myocardial fibrosis in 13%. It appeared most often
as midmyocardial enhancement in the septum and within the
basal inferiolateral segments of the LV wall [82]. Recently, it
was shown that DM1 patients, who present with an increase in
cardiac ECV, often have decreased strain values, which could
possibly indicate early cardiac pathology [79]. In addition to
annual follow-ups with 24h-ECG and TTE, the focus of car-
diologic care should lie on the decision when to implant PM-
ICD devices. International guidelines recommend to consider
PM placement even in patients with AV-block type I and, at
the same time, to assess the need for implantation of an ICD,
taking into consideration the future risk of ventricular arrhyth-
mias [83, 84].
DM2 is also transmitted in an AD fashion but instead of a
three nucleotide repeat, it is caused by a CCTG tetranucleotide
repeat located on the ZNF9 gene. Generally, DM 2 is consid-
ered to be a milder form with a later onset, usually in the 30th
to 50th decade of life. The characteristic muscular involve-
ment is more proximally orientated; therefore, the disease is
also known as proximal myotonic myopathy (PROMM).
Interestingly, patients commonly present with myalgias, rath-
er than myotonic symptoms, endocrine disturbances, and
presenile cataracts [85] (Table 2). In comparison to DM1,
PROMM has always been thought to have less cardiac in-
volvement, but cross-sectional studies suggest that the burden
of cardiac involvement is similar and in regards to atrial fibril-
lation and left ventricular dysfunction even higher in PROMM
[9, 86]. The left ventricular dysfunction should be of concern
as CMR can already detect myocardial fibrosis and an in-
crease in ECV in subclinical stages with preserved EF (Fig.
5). We could demonstrate that focal fibrosis and fat deposits
are detectable in 22% and 21% of patients with DM2, respec-
tively [87]. This opens the possibility to apply an anti-
remodeling therapy, e.g., with ACE inhibitors, to holt or even
prevent a further decline [88]. Large multicentric and prospec-
tive studies are missing on this topic so far. In general, we
follow a similar approach as outlined above for DM1. As
patients tend to be (a) older when symptoms start and (b) there
is a huge variety of symptoms the general practitioner and
cardiologist should be suspicious of an underlying genetic
abnormality. Care should be taken to properly manage comor-
bidities like HTN, diabetes mellitus, and hyperlipidemias.
Conclusion
MDs are rare diseases and therefore no large multicenter
studies exist that provide a high level of evidence. But the
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patients deserves special care regarding the early diagno-
sis of cardiac manifestations and optimal timing of heart
failure therapy, including devices if needed. Due to indi-
vidual predispositions, even mild initial dysfunction may
lead to severe heart failure over a time course of years.
CMR plays an increasing role in the diagnosis and clinical
care of patients suffering from MD. In most of these pa-
tients, the LV is either dilated or shows a reduction in
systolic function with a reduced EF. However, during
the last years, the awareness of a potential impact of the
right ventricle (RV) and the atria has increased.
Due to limitations associated with echocardiography
such as poor acoustic window and image quality, CMR
nowadays plays a key role in screening and management
of cardiomyopathies. This especially holds true for MD
patients, as their limited capacity to adjust the position for
a proper acoustic window reduces image quality even
more. Beyond precise assessment of volume and function,
CMR has the unique ability to differentiate myocardial
tissue including the detection and localization of edema
as well as focal and diffuse scars or fibrosis. In our
patients, we perform at least one diagnostic CMR scan
at baseline to identify the extent of cardiac involvement
in order to plan the follow-up examinations and visits.
Owing to the development of more robust and faster tech-
niques, scan time has been significantly reduced.
Unfortunately, it is still mistakenly believed that CMR is un-
suitable for very sick patients even though it can provide
unique information to guide further therapy. New technolog-
ical developments, like real-time and motion-corrected imag-
ing techniques, enable patients with reduced breath-hold ca-
pacities or arrhythmias to undergo CMR exams. Furthermore,
multi-slice LGE acquisitions are already available as non-
breath-hold techniques, reducing scan time by more than
60% (Fig. 6). In follow-up CMR exams, we often apply pro-
tocols without contrast media application, solely based on
parametric mapping.
CMR has gained increasing clinical relevance especial-
ly in recent years leading to class I recommendations in
many international cardiological guidelines. Further ran-
domized clinical trials with high level of evidence using
CMR as a robust, non-invasive technique are needed to
Fig. 5 A 57-year-old patient with DM2 and normal LV function (LVEF
58%). Detection of focal non-ischemic enhancement in the LV septum
(arrows) in a four-chamber view (1a) and short axis (1b). Late gadolinium
enhancement, corresponding with increased extracellular volume (ECV)
in a four-chamber view and short axis accordingly (arrows 2a, b)
220 Curr Heart Fail Rep (2021) 18:211–224
define the impact of early cardiac remodeling and myo-
cardial injury as well as to identify a relation between
cardiac involvement and arrhythmias on long-term prog-
nosis and on therapeutic decision-making in patients with
different types of MD. In the case of rare diseases, this
goal can be achieved by initiating registries that help sys-
tematically collect the data from these patients based on
CMR findings.
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